Clinical Trials
13 trialsNCT05497843 2025-04-03
Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)
Chipscreen Biosciences, Ltd.
Phase 2 Completed
NCT05336721 2025-03-24
A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC
Chipscreen Biosciences, Ltd.
Phase 2 Terminated
NCT04830813 2024-12-09
Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT04921527 2024-10-18
CHIPRO
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT05271292 2024-07-16
SCLC
Chipscreen Biosciences, Ltd.
Phase 1/2 Recruiting
NCT05371899 2024-07-15
Mass Balance Study of [14C]Chiauranib
Chipscreen Biosciences, Ltd.
Phase NA Completed
NCT03216343 2023-08-30
Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer
Chipscreen Biosciences, Ltd.
Phase 1 Completed
NCT03974243 2022-03-09
Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1/2 Completed
NCT03245190 2021-06-18
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
Chipscreen Biosciences, Ltd.
Phase 1/2 Completed
NCT03901118 2021-03-19
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
Chipscreen Biosciences, Ltd.
Phase 2 Completed
NCT03166891 2020-01-18
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Chipscreen Biosciences, Ltd.
Phase 1/2 Completed
NCT03074825 2019-07-24
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1 Terminated
NCT02122809 2016-06-17
Phase I Study of Chiauranib in Patients With Advanced Solid Tumors
Chipscreen Biosciences, Ltd.
Phase 1 Completed